Geert-Jan Mulder, MD
Geert-Jan Mulder MD, co-founding partner of Forbion, is an experienced life sciences investor who led multiple deals in both Europe and the US.
Geert-Jan led the firm’s successful investments in bluebird bio (NASDAQ:BLUE), where he served on the board until its IPO in 2013, supported the company’s clinical and regulatory strategy; and was involved in the in-licensing of the ALD program from Inserm (France) in 2009; Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006 where he was part of the AMPYRA® board panel to evaluate a new clinical endpoint in Multiple Sclerosis; and PanGenetics BV leading their Series B and sold to Abbott for USD190 million in 2009. Other past investments include Transave, where he served on the board until the merger with Insmed (NASDAQ:INSM) in 2010. In 2015 AM-Pharma B.V. (The Netherlands) closed an option deal with Pfizer for a total deal value of up to USD 600 million and Promedior (USA) and Bristol-Myers Squibb entered into an agreement providing exclusive right to acquire Promedior for a total deal value of up to USD 1.25 billion. Geert-Jan still serves on the boards of both companies.
Geert-Jan serves on the boards of Exosome Diagnostics (USA), Promedior (USA), Sanifit (Spain), ario pharma (UK) and Amakem N.V. (Belgium). In addition supports various Forbion portfolio companies in their clinical development strategies and regulatory matters. His efforts have supported the development of robust development programs, IND/ NDA filings, a Special Protocol Approval (SPA), and US / EU Orphan designations for several products.
Prior to joining ABN AMRO Capital Life Sciences (Forbion’s predecessor) in 2001, Geert-Jan received his Medical Degree from the University of Utrecht (NL) followed by a residency in ObGyn the University Medical Center. He was Medical Adviser at Searle (now Pfizer) in the field of Arthritis & Pain, being involved in the clinical development of Celebrex® and its European Advocate Development. At Byk Gulden (now Takeda) he became Clinical Research Manager, where his group was responsible for design and execution of early and late stage clinical trials forming the basis for two global product registrations: Daxas® and Alvesco® in fields of COPD and asthma. For both products he was a member of the Global Medical Marketing group and supported the line extension program of Pantozol®.